Professor Richard Lindley
Professor Richard Lindley is a world-renowned geriatrician and stroke physician. He leads a portfolio of international clinical trials and projects that reliably assess new treatments in older individuals (with a particular interest in stroke management). His work has made significant contributions to medical science and health care policy. He was senior investigator in studies demonstrating safety and efficacy in the elderly, of cholesterol lowering (Heart Protection Study) and antithrombotic and thrombolysis therapy (IST; IST-3), which helped to eradicate the upper age limit for the appropriate prescription of statins and thrombolytics, thereby saving lives and reducing the burden of cardiovascular disease in older individuals worldwide. He established and co-led the Third International Stroke Trial (IST-3) reporting the widely generalisable benefit of early thrombolytic treatment for ischemic stroke even in groups such as the very elderly, diabetics and cases of severe stroke (previously considered to have few evidence-based treatment options). Professor Lindley has co-chaired the Australian Stroke Coalition, the Stroke Topic Working Group for the Australian Commission on Safety and Quality in Health Care and the development of national stroke guidelines (in Australia and Scotland). His contribution to the National Stroke Audit Program helps implement best practice in stroke management and has been a major driver of government investment in new stroke units around Australia. Professor Lindley speaks regularly on the issue of consent provision and obtaining consent ethically from vulnerable groups such as the elderly and stroke patients. He is an Honorary Overseas Member of the Association of British Neurologists. He was Board Member of the National Stroke Foundation and Chair of its Clinical Council for nine years (2006-2015). He is currently the Deputy Head of School for Sydney Medical School and continues as a Principal Investigator at the Westmead Applied Research Centre (WARC).